AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX109.11+1.62 (+1.51%) ▲|SCHW92.56+0.72 (+0.78%) ▲|SO94.41+0.81 (+0.87%) ▲|SPG231.38+1.14 (+0.50%) ▲|T21.95-0.34 (-1.53%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN292.43-3.43 (-1.16%) ▼|UBER68.76-0.05 (-0.07%) ▼|UNH349.91-39.77 (-10.21%) ▼|UNP300.90+3.87 (+1.30%) ▲|UPS111.03+0.72 (+0.65%) ▲|USB58.28-0.90 (-1.52%) ▼|V415.22-1.55 (-0.37%) ▼|VZ46.13+0.20 (+0.44%) ▲|WFC80.92-1.77 (-2.14%) ▼|WMT127.36-0.16 (-0.13%) ▼|XOM160.58-6.63 (-3.97%) ▼|AAPL352.45+0.54 (+0.15%) ▲|ABBV286.01-6.81 (-2.33%) ▼|ABT104.48-0.23 (-0.22%) ▼|ACN227.49-11.79 (-4.93%) ▼|ADBE226.20-9.35 (-3.97%) ▼|AMAT352.30+3.07 (+0.88%) ▲|AMD530.14+26.73 (+5.31%) ▲|AMGN443.89-14.04 (-3.07%) ▼|AMT184.82+1.64 (+0.90%) ▲|AMZN267.74+9.85 (+3.82%) ▲|AVGO354.05+12.45 (+3.64%) ▲|AXP315.40-0.38 (-0.12%) ▼|BA162.91-1.00 (-0.61%) ▼|BAC48.91-0.53 (-1.07%) ▼|BKNG153.28-1.18 (-0.76%) ▼|BLK1,169.21-11.46 (-0.97%) ▼|BMY59.56-1.79 (-2.92%) ▼|BNY147.80-1.99 (-1.33%) ▼|BRK-B574.62-12.14 (-2.07%) ▼|C117.34-2.60 (-2.17%) ▼|CAT558.77-12.02 (-2.11%) ▼|CL98.85-0.76 (-0.76%) ▼|CMCSA25.24-0.07 (-0.28%) ▼|COF184.30-2.48 (-1.33%) ▼|COP134.40-5.08 (-3.64%) ▼|COST1,096.62-13.46 (-1.21%) ▼|CRM190.40-4.12 (-2.12%) ▼|CSCO97.18+2.07 (+2.18%) ▲|CVS81.35-4.46 (-5.20%) ▼|CVX205.88-8.47 (-3.95%) ▼|DE644.75-4.48 (-0.69%) ▼|DHR228.58+2.81 (+1.24%) ▲|DIS122.36+5.42 (+4.63%) ▲|DUK130.05+0.21 (+0.16%) ▲|EMR162.00+2.85 (+1.79%) ▲|FDX318.31-1.63 (-0.51%) ▼|GD349.04-6.59 (-1.85%) ▼|GE328.10+1.70 (+0.52%) ▲|GEV772.22-7.69 (-0.99%) ▼|GILD168.98-1.28 (-0.75%) ▼|GM82.13-1.92 (-2.28%) ▼|GOOG279.20+1.60 (+0.58%) ▲|GOOGL282.44+2.24 (+0.80%) ▲|GS873.18-4.34 (-0.49%) ▼|HD337.64-1.37 (-0.40%) ▼|HON222.70+3.74 (+1.71%) ▲|IBM228.53-2.56 (-1.11%) ▼|INTC54.67-0.50 (-0.91%) ▼|INTU313.24-7.55 (-2.35%) ▼|ISRG420.95-9.58 (-2.23%) ▼|JNJ272.70-6.00 (-2.15%) ▼|JPM324.11-5.85 (-1.77%) ▼|KO98.09-0.70 (-0.71%) ▼|LIN512.16-2.95 (-0.57%) ▼|LLY1,382.75-32.80 (-2.32%) ▼|LMT578.19-12.15 (-2.06%) ▼|LOW222.78+2.32 (+1.05%) ▲|LRCX211.67+0.98 (+0.47%) ▲|MA643.37-2.36 (-0.37%) ▼|MCD274.03-1.79 (-0.65%) ▼|MDLZ66.57-0.19 (-0.28%) ▼|MDT100.72-1.60 (-1.56%) ▼|META616.38-2.49 (-0.40%) ▼|MMM181.05+0.17 (+0.09%) ▲|MO76.26-1.20 (-1.55%) ▼|MRK137.78-5.59 (-3.90%) ▼|MS181.17-2.36 (-1.29%) ▼|MSFT508.29+2.05 (+0.40%) ▲|MU705.27-7.15 (-1.00%) ▼|NEE84.78+0.36 (+0.43%) ▲|NFLX59.82+0.14 (+0.23%) ▲|NKE36.31+0.46 (+1.28%) ▲|NOW90.59-2.31 (-2.49%) ▼|NVDA150.96-4.50 (-2.89%) ▼|ORCL113.89-1.11 (-0.97%) ▼|PEP141.87-0.15 (-0.11%) ▼|PFE28.06-0.41 (-1.44%) ▼|PG170.29-1.43 (-0.83%) ▼|PLTR156.67+0.11 (+0.07%) ▲|PM192.73-1.65 (-0.85%) ▼|QCOM159.81-6.86 (-4.12%) ▼|RTX197.45-0.55 (-0.28%) ▼|SBUX109.11+1.62 (+1.51%) ▲|SCHW92.56+0.72 (+0.78%) ▲|SO94.41+0.81 (+0.87%) ▲|SPG231.38+1.14 (+0.50%) ▲|T21.95-0.34 (-1.53%) ▼|TMO692.74+5.95 (+0.87%) ▲|TMUS164.02-3.88 (-2.31%) ▼|TSLA383.72+3.61 (+0.95%) ▲|TXN292.43-3.43 (-1.16%) ▼|UBER68.76-0.05 (-0.07%) ▼|UNH349.91-39.77 (-10.21%) ▼|UNP300.90+3.87 (+1.30%) ▲|UPS111.03+0.72 (+0.65%) ▲|USB58.28-0.90 (-1.52%) ▼|V415.22-1.55 (-0.37%) ▼|VZ46.13+0.20 (+0.44%) ▲|WFC80.92-1.77 (-2.14%) ▼|WMT127.36-0.16 (-0.13%) ▼|XOM160.58-6.63 (-3.97%) ▼|
8.9 C
New York
Thursday, November 19, 2026

Tag: 1

UK’s leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides

LONDON, June 12, 2026 /PRNewswire/ -- Get A Drip, one of the UK's largest providers of longevity health treatments, is strengthening its clinical leadership...

SHPT Unveils M5 & P5 Series: A New Cutting-edge Solution to Accelerate Large-Scale Hydrogen Energy Adoption

SHANGHAI, June 12, 2026 /PRNewswire/ -- On June 10, 2026, SHPT held its "New Core, New Journey" New Product Launch during the 10th International Hydrogen...

Form 8.5 (EPT/RI)-Treatt Plc

FORM 8.5 (EPT/RI)

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial7. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines7.

“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.”

The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common8. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines.

“Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido’s proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis’ commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.”

Primary endpoint results at Week 12 in the RemIND trial1

Loomis issues SEK 1,000 million in sustainability-linked bonds

STOCKHOLM, June 12, 2026 /PRNewswire/ -- Loomis AB has issued SEK 1,000 million in sustainability-linked bonds with a 5-year maturity and a floating interest...

PHX Energy Services Corp. Announces Quarterly Dividend

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- PHX Energy Services Corp. ("PHX Energy" or the "Corporation") is pleased to announce that its Board of Directors has declared a quarterly cash dividend of $0.20 per common share designated as an “eligible dividend” within the meaning of subsection 89(1) of the Income Tax Act (Canada), payable on July 15, 2026, to shareholders of record at the close of business on June 30, 2026.

Beijing China-Germany Forum for Industrial Cooperation and Development — China-Germany (China-Europe) Hidden Champions Forum 2026 Held

BEIJING, June 12, 2026 (GLOBE NEWSWIRE) -- On May 25, the Beijing China-Germany Forum for Industrial Cooperation and Development -- China-Germany (China-Europe) Hidden Champions Forum 2026 commenced at the China-Germany International Conference and Exhibition Center in Shunyi District, Beijing. Themed "Joint Innovation • Integrated Development", the forum is co-hosted by the Shunyi District People's Government and the European Senate of Economy, and jointly initiated by the International Cooperation Center (ICC) of the National Development and Reform Commission (NDRC), among others. The forum brought together over 400 Chinese and international participants, including nearly 100 political and business figures, as well as heads of Hidden Champion enterprises from Germany and other parts of Europe.

Binance Exchange Launches bStocks Tokenized Securities: 1:1 Backing and 24/7 Trading

ISLAMABAD, June 12, 2026 /PRNewswire/ -- Binance Exchange today announced the admission to trading of bStocks, fully-backed tokenized securities representing select U.S. stocks issued...

The Galien Foundation Honours Leaders in Life Sciences Innovation with the 2026 Prix Galien UK Awards

-- Winners across biotechnology, digital health, medical technology, pharmaceuticals, public sector, and health equity categories honoured at prestigious Awards Ceremony LONDON, June 12, 2026...

Electric Vehicle Market Expected to Grow at 7.73% CAGR to Reach US$ 1720.00 Billion by 2034

The electric vehicle market size is expected to reach US$1,720.00 billion by 2034 at a CAGR of 7.73% during the forecast period

CAPITAL INCREASE – Publication of the new denominator in accordance with Article 15 of the Law of 2 May 2007

Following the capital increase of €15 million (including the share premium) through an accelerated book building process (ABB) on 10 June 2026, 311,203 new shares are being issued today (12 June 2026).

KAPITAALVERHOGING – Bekendmaking van de nieuwe noemer overeenkomstig artikel 15 van de Wet van 2 mei 2007

Naar aanleiding van de kapitaalverhoging van 15 miljoen EUR (inclusief uitgiftepremie) via een versnelde orderboekprocedure (ABB) op 10 juni 2026, worden vandaag (12 juni 2026)  311.203 nieuwe aandelen uitgegeven.

Maritime Silk Road documentary wins silver Telly Award

HAIKOU, China, June 12, 2026 /PRNewswire/ -- A news report from chinadaily.com.cn The Chinese documentary Silk Road Sunken Treasures won the Silver Award in the General Documentary...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags1